When Antihistamines Aren’t Enough for Chronic Spontaneous Urticaria: What Happens Next?

TL;DR

• When standard-dose second-generation antihistamines do not control chronic spontaneous urticaria (CSU), current guidelines recommend reviewing treatment and may consider increasing one antihistamine up to four times the standard dose under medical supervision. This higher dosing is off-label.\[2\]
• Omalizumab remains an important next treatment option for CSU that remains uncontrolled despite high-dose antihistamines. Newer options, including dupilumab and remibrutinib, have also expanded the treatment landscape.\[2–4\]
• Corticosteroids can sometimes be used for short rescue periods during severe flares, but guidelines recommend against long-term systemic corticosteroid use in chronic urticaria.\[2\]
• In mama health's analysis of Italian CSU patient conversations, people described the escalation process as emotional and administrative as well as medical. Waiting lists, paperwork, repeated steroid use and the need to push for referrals came up again and again.\[1\]
• A treatment not working well enough does not mean there are no further options. The next step depends on previous treatments, disease burden, response, safety, local access and a healthcare professional's assessment.

What happens when antihistamines do not control chronic spontaneous urticaria?

When standard-dose antihistamines are not enough, CSU treatment usually moves through a stepwise escalation rather than immediately abandoning antihistamines.

Second-generation H1-antihistamines remain the first-line medication in the 2026 international urticaria guideline. Examples include cetirizine, bilastine, fexofenadine, desloratadine and rupatadine.\[2\]

If the licensed dose does not provide adequate control, the guideline recommends increasing the dose of a single second-generation H1-antihistamine up to fourfold rather than routinely combining several different antihistamines. Doses above four times the standard dose are not recommended. Antihistamine updosing above the licensed dose is off-label and should therefore be discussed with a healthcare professional.\[2\]

That distinction matters because patients may describe themselves as having "failed antihistamines" even though their treatment histories are much more complicated. Some have tried several drugs. Some have increased doses. Others have moved between treatments during flares.

Nearly every patient in mama health's Italian CSU patient conversations had tried an antihistamine somewhere along their journey.\[1\] But deliberately increasing the dose beyond the standard amount — the updosing step guidelines actually recommend — showed up in only a small share of those same journeys.

This is worth reading carefully rather than as a simple compliance gap. Patient stories don't consistently record exact doses, so this pattern may reflect incomplete documentation, differences in how care pathways work in practice, or both — not necessarily that most patients are being under-treated.

Why can antihistamines stop feeling like enough?

Antihistamines may reduce CSU symptoms without providing complete disease control.

CSU involves the activation of mast cells and the release of histamine and other inflammatory mediators. Blocking H1 histamine receptors can therefore help with itching and wheals, but the degree of response differs between people.

This variation is visible in patient accounts. Across the detailed CSU journeys mama health has analyzed, people repeatedly described medications such as cetirizine, bilastine, fexofenadine, desloratadine and rupatadine as simply "not enough." Many reported continuing itch, wheals or swelling despite changing antihistamines or increasing doses.\[1\]

The emotional effect appeared just as consistently. Patients used words such as frustrating, demoralising and unbearable when describing periods in which symptoms continued despite treatment.\[1\]

This experience is supported by wider CSU research. In the international ASSURE-CSU study of 673 adults with inadequately controlled CSU, the condition substantially affected quality of life, sleep, daily activities and work productivity.\[5\]

The goal of discussing treatment escalation is therefore not only to count hives. Sleep, work, social activities and the overall disruption caused by CSU can also provide useful context during medical appointments.

Should antihistamine doses be increased before moving to another treatment?

Current international guidance recommends considering antihistamine updosing before moving beyond H1-antihistamine treatment.

For people whose symptoms remain uncontrolled at the licensed dose, the 2026 international guideline recommends increasing one second-generation H1-antihistamine up to fourfold.\[2\]

This is not the same as taking extra medication independently.

Higher-than-licensed antihistamine dosing is off-label. The appropriate medicine and dose can depend on factors such as other medications, age, pregnancy, existing medical conditions and previous side effects.

Another important point is that guidelines generally favour increasing a single second-generation antihistamine rather than routinely mixing several different H1-antihistamines.\[2\]

For patients who have already cycled through multiple antihistamines, it can therefore be useful to clarify exactly what has been tried: which medicine, what dose, for how long and what happened.

Why do steroids often appear when antihistamines are not enough?

Systemic corticosteroids can rapidly suppress severe CSU flares, but they are not recommended as a long-term solution for chronic urticaria.

The 2026 international guideline recommends against prolonged systemic corticosteroid use in chronic urticaria. A short rescue course may sometimes be considered during an acute exacerbation, but this is different from relying on steroids repeatedly as maintenance treatment.\[2\]

The Italian patient data show how important this issue is in practice. Corticosteroids — both topical and systemic combined — showed up in over half of the patient journeys mama health reviewed.\[1\] That figure alone can't tell you how many patients specifically relied on repeated oral steroid rescue, since it lumps together very different uses of the same drug class.

What the detailed, in-depth patient narratives add is texture: repeated oral corticosteroid use appeared frequently as a bridge when antihistamines weren't providing enough relief. Patients often understood that steroids weren't intended as a long-term answer but described reaching for them during difficult flares because they felt they had few alternatives.\[1\]

This creates what patients may experience as a steroid trap: a medicine used to get through the immediate flare without resolving the longer-term question of what comes next.

If rescue corticosteroids are becoming a recurring part of someone's CSU experience, that history can be useful information to bring to a healthcare professional when discussing longer-term options.

When is omalizumab considered for chronic spontaneous urticaria?

Omalizumab is recommended as an add-on treatment when CSU remains uncontrolled despite high-dose second-generation H1-antihistamines.

Omalizumab is a monoclonal antibody that targets IgE. The 2026 international guideline continues to recommend it as the next major step in the treatment algorithm for people who do not obtain sufficient benefit from high-dose second-generation antihistamines.\[2\]

The guideline describes an initial CSU dose of 300 mg every four weeks as an add-on to antihistamine treatment. Individual treatment decisions and dosing should be made by the treating healthcare professional.\[2\]

For some patients, this transition can be significant. A meaningful minority of the patients in mama health's Italian conversations had reached omalizumab in their treatment journey.\[1\] That doesn't mean only that share of patients who qualified for a biologic actually received one — the data includes people at very different stages of disease and treatment, and someone's story can touch more than one treatment category.

What the detailed narratives add is context. Patients described waiting lists, Piano Terapeutico paperwork, clinicians who were initially hesitant to escalate treatment, and situations in which they felt they had to push for referral or specialist assessment.\[1\]

For these patients, moving beyond antihistamines was not simply a pharmacological decision. It could also be an access process.

Does omalizumab work for everyone with CSU?

Omalizumab can provide substantial benefit for many people with antihistamine-refractory CSU, but responses are not identical.

The international guideline notes that some people have an insufficient response at the licensed dose. It also describes specialist-led adjustments to dose or treatment interval in selected patients, although these approaches can be off-label.\[2\]

The mama health patient narratives show both ends of the experience. Some Italian patients described omalizumab as life-changing. Others reported an incomplete response, changing effectiveness over time, or symptoms returning after treatment was stopped.\[1\]

One particularly strong theme was the emotional impact of improvement followed by recurrence. Patients described the return of symptoms after a period of control as feeling like "falling back into the abyss."\[1\]

It's important to distinguish several experiences that may sound similar:

• Symptoms returning after omalizumab has been discontinued.
• Symptoms improving only partially from the beginning.
• Symptoms returning before the next scheduled dose.
• A response that appears to become less reliable while treatment continues.

These situations are not necessarily medically equivalent.

The guideline reports that relapse after stopping omalizumab can respond to treatment again. It also recognises that some patients have an insufficient response and may require specialist reassessment.\[2\]

Documenting when symptoms return and how they change can make this conversation more precise.

Are there newer treatments after antihistamines?

Yes. The CSU treatment landscape now includes more options than antihistamines, omalizumab and ciclosporin alone.

The 2026 international guideline includes dupilumab and remibrutinib as potential add-on treatments for antihistamine-refractory CSU, alongside omalizumab.\[2\]

The regulatory situation has also changed in Europe. Dupilumab is now authorised in the EU for moderate-to-severe CSU in patients aged 2 years and older whose disease is not adequately controlled by H1-antihistamines and who have not previously received anti-IgE treatment for CSU.\[3\]

Remibrutinib, an oral Bruton's tyrosine kinase inhibitor, is authorised in the EU for adults with CSU whose disease is not adequately controlled with H1-antihistamines.\[4\]

These approvals do not mean every treatment will be appropriate or immediately accessible to every patient. Age, previous therapy, contraindications, local prescribing rules, reimbursement and specialist assessment can all influence what is available in practice.

This is also why older descriptions of the CSU pathway as simply antihistamine → omalizumab → ciclosporin now need more nuance.

When is ciclosporin considered for CSU?

Ciclosporin is generally reserved for severe CSU when licensed treatment options have not provided sufficient control or are unavailable.

Ciclosporin suppresses parts of the immune response and has evidence of efficacy in chronic urticaria. However, the 2026 international guideline does not recommend it as standard treatment because of its safety profile, particularly with prolonged use. Its use for CSU is off-label.\[2\]

Very few of the patients in mama health's Italian data had reached ciclosporin — a small handful compared with those who'd tried antihistamines or omalizumab.\[1\] In the detailed journeys, it was often described with anxiety rather than optimism — patients mentioned worries about blood pressure, tremor and kidney health.\[1\]

These patient concerns help explain why reaching ciclosporin can feel very different from simply moving to "the next drug."

Specialist assessment and appropriate safety monitoring are particularly important when immunosuppressive treatments are considered.

Why does access matter when CSU treatment needs to be escalated?

Access matters because the guideline pathway on paper can look much simpler than the journey described by patients.

In the Italian narratives, escalation to advanced treatment was sometimes shaped by referral delays, waiting lists, administrative paperwork, treatment eligibility requirements, clinician hesitation, repeated appointments, and patients feeling they needed to advocate for further assessment.\[1\]

These experiences shouldn't be read as showing that every Italian CSU patient encounters the same barriers. They do show that treatment access is part of the patient experience, not a separate issue from the medicine itself.

This context matters for interpreting any given statistic about who reaches a biologic. A number alone can't establish why a person did or didn't receive one — the qualitative accounts provide that missing context by showing some of the barriers individual patients actually described.

For someone living through repeated flares, a delay measured in appointments or forms can feel very different from a neat step on a clinical treatment diagram.

Why are sleep, work and emotional burden important when antihistamines fail?

Sleep, work and emotional wellbeing are important because uncontrolled CSU affects much more than the skin.

In mama health's patient narratives, sleep loss, work disruption, cancelled plans and social withdrawal came up again and again.\[1\] Some patients also described being told that their symptoms were "just stress." This could leave them feeling dismissed, particularly when visible wheals were intermittent or had disappeared by the time of an appointment.\[1\]

Research reflects this wider burden. The ASSURE-CSU study found substantial effects on sleep and daily activities among inadequately controlled patients. More than 20% reported missing at least one hour of work per week, and average productivity impairment was 27%.\[5\]

These outcomes matter because CSU control is not only about what the skin looks like at one moment. A fuller picture may include how often itch interrupts sleep, whether angioedema is occurring, how often flares interfere with work or study, activities being cancelled or avoided, treatments being used during flares, and how long any improvement lasts.

Several patients in mama health's conversations also described online CSU communities as an important source of validation and practical information.\[1\] Patient communities can provide emotional support, although treatment information found online should still be discussed with a qualified healthcare professional.

What could you discuss with your doctor if antihistamines are not enough?

You could use your appointment to clarify what has already been tried, how much CSU is affecting daily life and which evidence-based options may be relevant next.

Questions that may help structure the conversation include:

• Have I had an adequate trial of a second-generation H1-antihistamine?
• Could we discuss whether antihistamine updosing is relevant in my situation?
• How would we decide whether my CSU is adequately controlled?
• If I keep needing corticosteroid rescue, could we discuss the longer-term treatment plan?
• Could we discuss whether I meet the criteria for an add-on treatment?
• If omalizumab is being considered, what are the local referral, approval or access steps?
• If my response to omalizumab is incomplete or changes over time, how would that be assessed?
• Which newer CSU treatments are licensed and accessible in my situation?
• How should I record sleep disruption, work impact, hives or swelling so I can explain the pattern clearly?

These questions are conversation prompts, not recommendations for a specific treatment. The appropriate next step depends on an individual's history and should be decided with a healthcare professional.

What should you remember if your CSU is still uncontrolled?

Antihistamine-refractory CSU can require several treatment steps, and the process does not always follow a straight line.

Current guidance provides a structured escalation pathway, but real patient journeys show what that pathway can miss: repeated rescue medication, waiting, uncertainty, inconsistent responses and the invisible effects on sleep, work and confidence.

mama health's Italian patient data underline that gap. Nearly every patient had tried an antihistamine at some point. More than half had needed corticosteroids of some kind along the way. A meaningful minority had reached omalizumab. Very few had gotten as far as ciclosporin.\[1\]

Those patterns don't explain every clinical decision. They do show how differently each stage of treatment shows up in real-world patient stories.

For patients, "what happens next?" is therefore not only a question about the next medicine. It can also mean understanding whether the current treatment has been fully explored, documenting how CSU is affecting daily life, knowing that additional options exist, and having a clearer conversation about access and next steps.

Disclaimer: This content is informational and not medical advice. mama health offers information and support and does not replace a doctor.